• C00-D49 Neoplasms.
Conditions
Interventions
Azithromycin oral suspension 300mg twice daily from first day of chemotherapy until engraftment day plus standard supportive care for mucositis in intervention group versus standard care of mucositis
Treatment - Drugs
Sponsors
Maria Tavakoli-Ardakani
Eligibility
Sex/Gender
All
Age
12 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients hospitalized in bone marrow transplantation and patients undergoing chemotherapy;Patients satisfaction to participate in the study The exclusion criteria: Unwillingness of patients to continue;Allergic reactions to medication or other subunits of mouthwash
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mucositis. Timepoint: first day of chemotherapy until engraftment day. Method of measurement: WHO scoring system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever grade. Timepoint: From the first day of chemotherapy until engraftment time. Method of measurement: Submit a fever above 38.5 ° C for patients.;The need fortotal parenteral nutrition(TPN). Timepoint: During the study period. Method of measurement: SignTthe daysof parenteral nutrition intake. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohadeseh Zeraatkar
Students Research committee, School of pharmacy, Shahid Beheshti University of Medical Sciences
Outcome results
None listed